A Phase 4 interventional study of Dapagliflozin in Diabetes Mellitus, Type 2 and Kidney Function Tests, sponsored by AstraZeneca. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-28.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 154th largest by enrollment, is one of 13 that started in 2017, is one of 77 in phase 4, and was the 96th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 13 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 239th largest by enrollment of the 280 interventional ones that give a count, is one of 22 that started in 2017, is one of 28 in phase 4, and was the 280th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
Drug: Dapagliflozin
T2DM subjects with an eGFR (CKD-EPI) between \>90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between \>85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between \>75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
Drug: Dapagliflozin
Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
Drug: Dapagliflozin
The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
Change in 24-hour Sodium Excretion From Baseline to Start of Treatment
Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.
Time frame: From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)
Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up
Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).
Time frame: From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)
Change in 24-hour Glucose Excretion From Baseline to Start of Treatment
Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).
Time frame: From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)
Change in 24-hour Glucose Excretion From Baseline to End of Treatment
Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)
Time frame: From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)
Change in 24-hour Glucose Excretion From End of Treatment to Follow-up
Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).
Time frame: From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)
Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment
Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)
Time frame: From baseline (Day -1) to start of treatment (Day 4)
Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment
Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).
Time frame: From baseline (Day -1) to end of treatment (Day 13)
Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up
Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).
Time frame: From end of treatment (Day 13) to end of follow-up (Day 18)
Change in Plasma Volume From Baseline to Start of Treatment
Change in plasma volume from baseline to start of treatment (Day 4).
Time frame: From baseline (Day 1) to start of treatment (Day 4)
Change in Plasma Volume From Baseline to End of Treatment
Change in plasma volume from baseline to end of treatment (Day 14).
Time frame: From baseline (Day 1) to end of treatment (Day 14)
Change in Plasma Volume From End of Treatment to End of Follow-up
Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).
Time frame: From end of treatment (Day 14) to end of follow-up (Day 18)
Change in Extracellular Volume From Baseline to Start of Treatment
Change in extracellular volume from baseline to start of treatment (Day 4).
Time frame: From baseline (Day 1) to start of treatment (Day 4)
Change in Extracellular Volume From Baseline to End of Treatment
Change in extracellular volume from baseline to end of treatment (Day 14).
Time frame: From baseline (Day 1) to end of treatment (Day 14)
Change in Extracellular Volume From End of Treatment to End of Follow-up
Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).
Time frame: From end of treatment (Day 14) to end of follow-up (Day 18)
Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)
Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).
Time frame: From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)
Pharmacokinetics of Dapagliflozin on Day 4 and Day 14
Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)
Time frame: At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)
Number of Patients With AEs and SAEs
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.
Time frame: From Day 1 until Day 18 (Follow-up)
The study was conducted between 12-Jul-2017 and 20-Mar-2020. Patients who met all the inclusion and none of the exclusion criteria were enrolled in the study.
| Milestone | Group 2 | Group 3 |
|---|---|---|
| Started | 17 | 7 |
| Completed | 17 | 7 |
| Not completed | 0 | 0 |
Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.
| mmol/24 hour | Group 2 | Group 3 |
|---|---|---|
| Change in 24-hour Sodium Excretion From Baseline to Start of Treatment | -5.33 (-53.667 to 44.000) | -27.67 (-69.334 to 13.334) |
Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).
| mmol/24 hour | Group 2 | Group 3 |
|---|---|---|
| End of treatment vs baseline | 2.67 (-64.000 to 143.167) | -23.83 (-107.000 to 0.667) |
| Follow-up vs end of treatment | 1.33 (-135.334 to 25.000) | 6.17 (-70.333 to 20.333) |
Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).
| mmol/24 hour | Group 2 | Group 3 |
|---|---|---|
| Change in 24-hour Glucose Excretion From Baseline to Start of Treatment | 302.61 (191.472 to 635.726) | 43.93 (12.050 to 132.333) |
Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)
| mmol/24 hour | Group 2 | Group 3 |
|---|---|---|
| Change in 24-hour Glucose Excretion From Baseline to End of Treatment | 283.40 (155.876 to 762.801) | 29.88 (15.450 to 113.300) |
Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).
| mmol/24 hour | Group 2 | Group 3 |
|---|---|---|
| Change in 24-hour Glucose Excretion From End of Treatment to Follow-up | -168.43 (-376.561 to -107.596) | -37.02 (-74.733 to -10.584) |
Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)
| mmHg | Group 2 | Group 3 |
|---|---|---|
| Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment | -5.4810 (-13.6610 to 5.6100) | -8.9730 (-24.6570 to 2.7210) |
Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).
| mmHg | Group 2 | Group 3 |
|---|---|---|
| Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment | -5.9385 (-16.0060 to 0.9160) | -10.3290 (-23.4160 to 16.2160) |
Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).
| mmHg | Group 2 | Group 3 |
|---|---|---|
| Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up | 2.5140 (-10.3420 to 8.4590) | -2.6590 (-16.3110 to 7.4680) |
Change in plasma volume from baseline to start of treatment (Day 4).
| Litres | Group 2 | Group 3 |
|---|---|---|
| Change in Plasma Volume From Baseline to Start of Treatment | -0.1440 (-1.7819 to 2.6385) | -0.1139 (-2.0340 to 0.0232) |
Change in plasma volume from baseline to end of treatment (Day 14).
| Litres | Group 2 | Group 3 |
|---|---|---|
| Change in Plasma Volume From Baseline to End of Treatment | -0.2122 (-2.8346 to 1.1073) | 2.0557 (2.0557 to 2.0557) |
Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).
| Litres | Group 2 | Group 3 |
|---|---|---|
| Change in Plasma Volume From End of Treatment to End of Follow-up | 0.6464 (-1.5016 to 1.6410) | — |
Change in extracellular volume from baseline to start of treatment (Day 4).
| Litres | Group 2 | Group 3 |
|---|---|---|
| Change in Extracellular Volume From Baseline to Start of Treatment | -0.5783 (-2.7027 to 0.7959) | -0.4553 (-1.3758 to 0.2282) |
Change in extracellular volume from baseline to end of treatment (Day 14).
| Litres | Group 2 | Group 3 |
|---|---|---|
| Change in Extracellular Volume From Baseline to End of Treatment | 0.1248 (-1.4948 to 0.9852) | -0.1427 (-0.6101 to 1.0055) |
Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).
| Litres | Group 2 | Group 3 |
|---|---|---|
| Change in Extracellular Volume From End of Treatment to End of Follow-up | 0.1784 (-0.6507 to 0.9780) | 0.1394 (-0.3045 to 0.9014) |
Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).
| mg/mmol | Group 2 | Group 3 |
|---|---|---|
| Start of treatment vs baseline | -0.07 (-30.750 to 6.700) | -5.83 (-35.300 to 0.300) |
| End of treatment vs baseline | -0.04 (-17.250 to 0.737) | -7.28 (-35.733 to 0.467) |
| Follow-up vs end of treatment | 0.07 (-0.243 to 51.667) | -0.19 (-2.967 to 6.367) |
Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)
| ng/mL | Group 2 | Group 3 |
|---|---|---|
| Day 4, Pre-dose | 4.58 ± 134.88 | 19.78 ± 116.54 |
| Day 14, Pre-dose | 4.54 ± 46.60 | 15.26 ± 41.97 |
| Day 14, 1 h | 57.46 ± 110.66 | 63.83 ± 150.41 |
| Day 14, 2 h | 46.47 ± 49.30 | 60.41 ± 140.69 |
| Day 14, 4 h | 29.71 ± 47.38 | 47.83 ± 100.41 |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.
| Patients | Group 2 | Group 3 |
|---|---|---|
| Any AE | 6 | 2 |
| AEs judged as causally related to dapagliflozin | 4 | 0 |
| AEs leading to death | 0 | 0 |
| SAEs (including outcomes = death) | 0 | 0 |
| SAEs causally related to dapagliflozin | 0 | 0 |
| AEs leading to permanent discontinuation of dapagliflozin | 0 | 0 |
| SAEs leading to permanent discontinuation of dapagliflozin | 0 | 0 |
| Hypoglycaemia AEs | 0 | 0 |
| Hypoglycaemia AEs leading to permanent discontinuation of dapagliflozin | 0 | 0 |
Collected over Day 1 until Day 18 (FU). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 2 | 0/17 (0%) | 0/17 (0%) | 6/17 (35.3%) |
| Group 3 | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Event | Group 2 | Group 3 |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/17 | 1/7 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/17 | 1/7 |
| Head discomfortNervous system disorders | 2/17 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 1/17 | 0/7 |
| NauseaGastrointestinal disorders | 1/17 | 0/7 |
| FatigueGeneral disorders | 1/17 | 0/7 |
| Genital infectionInfections and infestations | 1/17 | 0/7 |
| InfluenzaInfections and infestations | 1/17 | 0/7 |
| FallInjury, poisoning and procedural complications | 1/17 | 0/7 |
| SomnolenceNervous system disorders | 1/17 | 0/7 |
Safety Set: All patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.
| Age, Customized(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 80 years | 17 | 7 | 24 |
| >=80 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| Female | 6 | 2 | 8 |
| Male | 11 | 5 | 16 |
| Race (NIH/OMB)(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 16 | 7 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2017 to primary completion in Mar 2020, 32 months.
Results were first posted in May 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin